Arcturus Therapeutics Revenue
Biotechnology Research • 
San Diego, California, United States • 101-200 Employees
Arcturus Therapeutics revenue & valuation
| Annual revenue | $122,200,000 |
| Revenue per employee | $702,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $390,800,000 |
| Total funding | $9,000,000 |
Key Contacts at Arcturus Therapeutics
Andrew Sassine
Chief Financial Officer And Board Of Director
Teri Workman
Associate Director, Clinical Supply Chain
Rodrigo Yelin
Director, Program Management
Narae Lee
Associate Director
Kumar Rajappan
Sr. Director And Head Of Formulation Discovery Development And Delivery
Azad Kumar
Associate Director Analytical Development
Annalee Ledesma
Director Program Management
Grishma Acharya
Associate Director
Cristiano Sacchetti
Director, Bioanalytical - Translational Biology
Deep Patel
Associate Director - Head Of Global Msat & Technology Transfer, Drug Product
Company overview
| Headquarters | 10628 Science Center Drive, Suite 250, San Diego, CA 92121, US |
| Phone number | +18589002660 |
| Website | |
| NAICS | 541714 |
| SIC | 873 |
| Keywords | Development, Leadership, RNA, Partnerships, Discovery, Innovation, Lipids, Rare Diseases, Therapeutics, Vaccines, Cystic Fibrosis, HBV, Mrna, Covid-19, Coronavirus, Lunar, Lipid-Mediated Delivery, Otc Deficiency, Starr, Mrna Medicine, Glycogen Storage Disease |
| Founded | 2013 |
| Employees | 101-200 |
| Socials |
Arcturus Therapeutics Email Formats
Arcturus Therapeutics uses 3 email formats. The most common is {first name} (e.g., john@arcturusrx.com), used 97.2% of the time.
| Format | Example | Percentage |
|---|---|---|
{first name} | john@arcturusrx.com | 97.2% |
{first initial}.{last name} | j.doe@arcturusrx.com | 1.4% |
{first initial}{last name} | jdoe@arcturusrx.com | 1.4% |
About Arcturus Therapeutics
Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) a commercial messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics and infectious disease vaccines with enabling technologies: (i) LUNAR® lipid-mediated delivery, (ii) STARR® mRNA technology (sa-mRNA) and (iii) mRNA drug substance along with drug product manufacturing expertise. Arcturus developed KOSTAIVE®, the first self-amplifying messenger RNA (sa-mRNA) COVID vaccine in the world to be approved. Arcturus has an ongoing global collaboration for innovative mRNA vaccines with CSL Seqirus, and a joint venture in Japan, ARCALIS, focused on the manufacture of mRNA vaccines and therapeutics. Arcturus’ pipeline includes RNA therapeutic candidates to potentially treat OTC deficiency and cystic fibrosis (CF), along with its partnered mRNA vaccine programs for SARS-CoV-2 (COVID-19) and influenza. Arcturus’ versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, circular RNA, antisense RNA, self-amplifying RNA, DNA, and gene editing therapeutics. Arcturus' technologies are covered by its extensive patent portfolio (over 500 patents and patent applications in the U.S., Europe, Japan, China, and other countries).
Employees by Management Level
Total employees: 101-200
Seniority
Employees
Employees by Department
Arcturus Therapeutics has 91 employees across 13 departments.
Departments
Number of employees
Arcturus Therapeutics Tech Stack
Discover the technologies and tools that power Arcturus Therapeutics's digital infrastructure, from frameworks to analytics platforms.
CDN
Hosting
Security
Tag managers
Miscellaneous
Programming languages
Blogs
Font scripts
JavaScript libraries
Video players
Maps
Databases
Netherlands
Australia
United Kingdom
Frequently asked questions
4.8
40,000 users
